Facilitating cells in tolerance induction for kidney transplantation

Area of Science:

• Immunology
• Transplantation Biology
• Cell Therapy

Background:

• Solid organ transplantation necessitates lifelong immunosuppression to prevent rejection.
• Current immunosuppressive drugs increase risks of infection, cancer, and incur significant costs.
• Minimizing or eliminating antirejection drugs is a major goal in transplantation.

Purpose of the Study:

• To evaluate the clinical outcomes of a CD8/TCR facilitating cell-based hematopoietic stem cell transplant (FCRx) approach.
• To elucidate the science behind FCRx for inducing renal allograft tolerance.
• To assess the potential for avoiding graft-versus-host disease and long-term immunosuppression in living donor kidney transplant recipients.

Main Methods:

• Utilized a nonmyeloablative conditioning regimen.
• Employed facilitating cells and stem cells from donor mobilized peripheral blood mononuclear cells.
• Established durable hematopoietic macrochimerism in mismatched recipients.

Main Results:

• Achieved durable hematopoietic macrochimerism in mismatched recipients.
• Demonstrated donor-specific tolerance in persistently chimeric recipients.
• Successfully weaned recipients off immunosuppressive drugs over 12 months.

Conclusions:

• FCRx enables durable hematopoietic macrochimerism and tolerance induction in kidney transplant recipients.
• Recipients maintained stable renal function without developing acute or chronic graft-versus-host disease.
• This cell-based approach offers a pathway to eliminate long-term immunosuppression after transplantation.